Stem cell company Intellicell facing new financial wrinkles
It’s difficult to make it as a biotech company and I would say stem cell biotechs in general may have an even rougher time. One such company, Intellicell (Intellicell Biosciences, Inc), is showing a...
View ArticleWhat is the top stem cell biotech of 2014? Take our poll
What is the most exciting, important, promising, all-around awesome stem cell biotech of 2014? Vote and tell us why in the comments.
View ArticleTop 20 Stem Cell Predictions for 2015
Every year I do a list of top predictions for the coming year for the stem cell and regenerative medicine field. For example, you can see past top 10 predictions lists for 2013 and 2014. What’s in...
View ArticleAt mid-year, how are my top 20 stem cell predictions for 2015 doing?
Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly...
View ArticleMesoblast stock on hold: Poll if you expect good or bad news
Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is...
View ArticleWhat is your favorite stem cell/regen med biotech & why?
I’m putting together a list of stem cell and regenerative medicine biotech companies for a blog post, including both public and private. I’ve got a good list already, but want it to be fairly...
View ArticleShot to the heart: J&J punts on Capricor & its cardiac stem cell program
How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad...
View ArticleMesoblast gets FDA RMAT; List of 10 total designations so far
Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an...
View ArticleTop 20 predictions for stem cells & regenerative medicine in 2018
Every year I look into my stem cell crystal ball and make predictions for our field including regenerative medicine. Well, I don’t really look into a crystal ball, but I try to use a combination of...
View ArticleStem cell company Intellicell facing new financial wrinkles
It’s difficult to make it as a biotech company and I would say stem cell biotechs in general may have an even rougher time. One such company, Intellicell (Intellicell Biosciences, Inc), is showing a...
View ArticleWhat is the top stem cell biotech of 2014? Take our poll
What is the most exciting, important, promising, all-around awesome stem cell biotech of 2014? Vote and tell us why in the comments. The post What is the top stem cell biotech of 2014? Take our poll...
View ArticleTop 20 Stem Cell Predictions for 2015
Every year I do a list of top predictions for the coming year for the stem cell and regenerative medicine field. For example, you can see past top 10 predictions lists for 2013 and 2014. What’s in...
View ArticleAt mid-year, how are my top 20 stem cell predictions for 2015 doing?
Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly...
View ArticleMesoblast stock on hold: Poll if you expect good or bad news
Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is...
View ArticleWhat is your favorite stem cell/regen med biotech & why?
I’m putting together a list of stem cell and regenerative medicine biotech companies for a blog post, including both public and private. I’ve got a good list already, but want it to be fairly...
View ArticleWhy Lanza and I sold ACT stock
It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol...
View ArticleStem Cell Biotech Advanced Cell Technology (ACT) gets $35 million
Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are...
View ArticleFDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36
This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the...
View Article24 cell therapy & stem cell stocks I’m following
Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. These biotechs have ups and downs, sometimes at the same time. This is kind...
View ArticleStem Cell Biotech Advanced Cell Technology (ACT) gets $35 million
Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are...
View Article